Jefferies analyst Maury Raycroft upgraded BioCryst to Buy from Hold with an $11 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BCRX:
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst sees 2023 global net ORLADEYO revenue no less than $320M
- BioCryst reports Q2 adjusted EPS (24c), consensus (23c)
- BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
- Is BCRX a Buy, Before Earnings?